Page last updated: 2024-11-12

ginsenoside rh1

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ginsenoside Rh1: RN given for (3beta,6alpha,12beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(20S)-ginsenoside Rh1 : A tetracyclic triterpenoid that is (20S)-protopanaxadiol which is substituted by beta-D-glucoside at the 6alpha position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID12855920
CHEMBL ID466844
CHEBI ID142487
MeSH IDM0386849

Synonyms (33)

Synonym
BIDD:ER0183
ginsenoside rh1
CHEMBL466844
CHEBI:142487
(20s)-ginsenoside rh1
(2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-oxidanyl-hept-5-en-2-yl]-3,12-bis(oxidanyl)-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-6-yl]oxy]oxane-3,4,5-
A834283
ginsenoside rh(1)
ginsenoside g-rh(1)
unii-xbr6f7g8fu
beta-d-glucopyranoside, (3beta,6alpha,12beta)-3,12,20-trihydroxydammar-24-en-6-yl
xbr6f7g8fu ,
S9129
AKOS025311542
CS-3834
Q-100729
HY-N0604
bdbm50023447
sanchinoside rh1
sanchinoside b2
prosapogenin a2
20(s)-ginsenoside rh1
ginsenoside rh1, analytical standard
ginsenoside rh1, (20s)-
.beta.-d-glucopyranoside, (3.beta.,6.alpha.,12.beta.)-3,12,20-trihydroxydammar-24-en-6-yl
s-ginsenoside rh1
(2r,3r,4s,5s,6r)-2-{[(1s,3ar,3br,5s,5ar,7s,9ar,9br,11r,11ar)-7,11-dihydroxy-1-[(2s)-2-hydroxy-6-methylhept-5-en-2-yl]-3a,3b,6,6,9a-pentamethyl-hexadecahydro-1h-cyclopenta[a]phenanthren-5-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
AS-75346
(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,10r,12r,14r,17s)-3,12-dihydroxy-17-[(2r)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-6-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
HMS3886D18
DTXSID80979245
CCG-270315
C22129

Research Excerpts

Effects

ExcerptReferenceRelevance
"Ginsenoside Rh1 has been reported to possess antiallergic and anti-inflammatory activities, but its effects on monocytes remain to be determined. "( Ginsenoside Rh1 inhibits the invasion and migration of THP-1 acute monocytic leukemia cells via inactivation of the MAPK signaling pathway.
Cha, SW; Choi, YJ; Lee, SG; Yoon, JH, 2011
)
3.25

Treatment

Treatment with ginsenoside Rh1 significantly increased the proliferation and decreased the apoptosis of ox-LDL-treated VECs in a dose-dependent manner. The treatment abolished the cytoprotective phenotype of Tat-transduced CHME5 cells as well as D3-infected human primary macrophages.

ExcerptReferenceRelevance
"Treatment with ginsenoside Rh1 significantly increased the proliferation and decreased the apoptosis of ox-LDL-treated VECs in a dose-dependent manner."( Effect of Ginsenoside Rh1 on Proliferation, Apoptosis, and Oxidative Stress in Vascular Endothelial Cells by Regulation of the Nuclear Erythroid 2-related Factor-2/Heme Oxygenase-1 Signaling Pathway.
Jiang, Y; Shi, Y; Xu, H; Yu, K; Zhang, X, 2022
)
1.46
"Treatment with ginsenoside Rh1 in the presence of lipopolysaccharide/cycloheximide (LPS/CHX) potently abolished the cytoprotective phenotype of Tat-transduced CHME5 cells as well as D3-infected human primary macrophages."( Ginsenoside Rh1 eliminates the cytoprotective phenotype of human immunodeficiency virus type 1-transduced human macrophages by inhibiting the phosphorylation of pyruvate dehydrogenase lipoamide kinase isozyme 1.
Jeong, JJ; Kim, B; Kim, DH, 2013
)
2.17
"Treatment with ginsenoside Rh1 inhibited adipogenesis, as evidenced by Oil red O staining and lipid droplet extraction assay."( Ginsenoside Rh1 ameliorates high fat diet-induced obesity in mice by inhibiting adipocyte differentiation.
Gu, W; Kim, DH; Kim, KA, 2013
)
2.17

Pharmacokinetics

ExcerptReferenceRelevance
" The method has been successfully used for the pharmacokinetic studies in rats."( Determination of 20(S)-ginsenoside Rh1 and its aglycone 20(S)-protopanaxatriol in rat plasma by sensitive LC-APCI-MS method and its application to pharmacokinetic study.
Chen, X; Hao, H; Lai, L; Liu, Y; Ren, H; Wang, G, 2009
)
0.66
" However, its pharmacokinetic characteristics and metabolic fate have never been reported."( Characterization of pharmacokinetic profiles and metabolic pathways of 20(S)-ginsenoside Rh1 in vivo and in vitro.
Chen, X; Hao, H; Lai, L; Liu, Y; Wang, G; Wang, Q; Zheng, C, 2009
)
0.58
"To study the pharmacokinetics of ginsenosides Rg1 and its metabolites after iv and oral administration in Wistar rats, the LC-MS/MS method was selected to determine ginsenosides Rg1 and its metabolites in plasma and their pharmacokinetic parameters were calculated."( [Pharmacokinetics of ginsenosides Rg1 and its metabolites in rats].
Feng, L; Hu, CJ; Yu, LY, 2010
)
0.36

Bioavailability

ExcerptReferenceRelevance
"Due to intestinal cytochrome P450 (CYP450)-mediated metabolism and P-glycoprotein (P-gp) efflux, poor oral bioavailability hinders ginsenoside-Rh1 (Rh1) and ginsenoside-Rh2 (Rh2) from clinical application."( Preparation and evaluation of self-microemulsions for improved bioavailability of ginsenoside-Rh1 and Rh2.
Chang, Q; Hu, X; Liao, Y; Liu, C; Liu, X; Pan, R; Yang, F; Yu, SK; Zhou, J, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
beta-D-glucosideAny D-glucoside in which the anomeric centre has beta-configuration.
12beta-hydroxy steroid
tetracyclic triterpenoidAny triterpenoid consisting of a tetracyclic skeleton.
ginsenosideTriterpenoid saponins with a dammarane-like skeleton originally isolated from ginseng (Panax) species. Use of the term has been extended to include semi-synthetic derivatives.
3beta-hydroxy steroidA 3-hydroxy steroid in which the 3-hydroxy substituent is in the beta-position.
3beta-hydroxy-4,4-dimethylsteroidAny 3beta-hydroxy steroid which is substituted by two methyl groups at position 4.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
ginsenosides biosynthesis225
ginsenosides biosynthesis1032

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aldo-keto reductase family 1 member B1Homo sapiens (human)IC50 (µMol)200.00000.00101.191310.0000AID1161379
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (15)

Processvia Protein(s)Taxonomy
retinoid metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
epithelial cell maturationAldo-keto reductase family 1 member B1Homo sapiens (human)
renal water homeostasisAldo-keto reductase family 1 member B1Homo sapiens (human)
carbohydrate metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
C21-steroid hormone biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
L-ascorbic acid biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
regulation of urine volumeAldo-keto reductase family 1 member B1Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
negative regulation of apoptotic processAldo-keto reductase family 1 member B1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
fructose biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
cellular hyperosmotic salinity responseAldo-keto reductase family 1 member B1Homo sapiens (human)
metanephric collecting duct developmentAldo-keto reductase family 1 member B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
retinal dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B1Homo sapiens (human)
electron transfer activityAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glyceraldehyde oxidoreductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
L-glucuronate reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member B1Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
extracellular spaceAldo-keto reductase family 1 member B1Homo sapiens (human)
nucleoplasmAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID359484Hepatoprotective activity in mouse hepatocytes assessed protection against D-galactosamine/TNFalpha-induced cell death at 200 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID359683Hepatoprotective activity in mouse hepatocytes assessed protection against D-galactosamine/TNFalpha-induced cell death at 100 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID337110Hepatoprotective activity against D-galactosamine/LPS-induced liver injury in ddY mouse assessed as inhibition of serum aspartate transaminase level at 100 mg/kg, ip administered 1 hr before D-galactosamine/LPS challenge by Reitman-Frankel method2003Journal of natural products, Jul, Volume: 66, Issue:7
Structures of new dammarane-type Triterpene Saponins from the flower buds of Panax notoginseng and hepatoprotective effects of principal Ginseng Saponins.
AID359493Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death at 50 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID359487Hepatoprotective activity in mouse hepatocytes assessed protection against D-galactosamine/TNFalpha-induced cell death at 50 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID337107Hepatoprotective activity against D-galactosamine/LPS-induced liver injury in ddY mouse assessed as inhibition of serum alanine transaminase level at 100 mg/kg, ip administered 1 hr before D-galactosamine/LPS challenge by Reitman-Frankel method2003Journal of natural products, Jul, Volume: 66, Issue:7
Structures of new dammarane-type Triterpene Saponins from the flower buds of Panax notoginseng and hepatoprotective effects of principal Ginseng Saponins.
AID359488Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death dosed administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID359494Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in mouse hepatocytes assessed cell survival rate at 100 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs by MTT assay2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID359682Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in mouse hepatocytes assessed cell survival rate at 50 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs by MTT assay2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID359495Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in mouse hepatocytes assessed cell survival rate at 200 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs by MTT assay2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID1161379Inhibition of human recombinant aldose reductase using DL-glyceraldehyde, HRAR and beta-NADPH incubated for 10 mins by spectrophotometry2014Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18
20(S)-Ginsenoside Rh2 as aldose reductase inhibitor from Panax ginseng.
AID1255693Activation of SIRT1 (unknown origin) after 45 mins by NAD/NADH enzyme-based fluorometric assay2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
New SIRT1 activator from alkaline hydrolysate of total saponins in the stems-leaves of Panax ginseng.
AID359489Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death at 100 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID1255692Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
New SIRT1 activator from alkaline hydrolysate of total saponins in the stems-leaves of Panax ginseng.
AID359490Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death at 200 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID1255691Cytotoxicity against human HL60 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
New SIRT1 activator from alkaline hydrolysate of total saponins in the stems-leaves of Panax ginseng.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (70)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's22 (31.43)29.6817
2010's30 (42.86)24.3611
2020's18 (25.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.99 (24.57)
Research Supply Index4.26 (2.92)
Research Growth Index5.62 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.43%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other69 (98.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]